Search

The article discusses a clinical trial, NCT06740630, focusing on the immune response and safety of an investigational varicella vaccine compared to an approved varicella vaccine in healthy children aged 12 to 15 months. The study aims to evaluate lot-to-lot consistency and immunogenicity. The trial involves administering different lots of vaccines to participants and monitoring their immune responses and adverse events. The study is not yet recruiting participants and is set to be completed by May 28, 2027. [Extracted from the article]

A study conducted in Wuxi, China, analyzed the sero-epidemiological characteristics of varicella in healthy children after receiving two doses of varicella vaccine. The research found that the seropositivity and geometric antibody titer were higher in vaccinated subjects compared to those who had not been vaccinated. The study concluded that two-dose vaccination with varicella vaccine is an effective prevention strategy and should be included in national immunization programs. For more information, the full article can be accessed at https://doi.org/10.1080/21645515.2024.2432118. [Extracted from the article]

A Phase 3a clinical trial is being conducted to evaluate the safety of an investigational varicella vaccine (VNS Vaccine) compared to Varivax in healthy children aged 12 to 15 months who have not had varicella or received a varicella vaccination. The study aims to assess the tolerability of the investigational vaccine through various outcome measures related to adverse events. The trial is not yet recruiting participants and is expected to be completed by December 3, 2026. [Extracted from the article]

Researchers at Complejo Asistencial Universitario de Leon have conducted a study on the immunogenicity of a new herpes zoster recombinant subunit vaccine in patients with immune-mediated rheumatic diseases (IMRDs) who are being treated with JAK inhibitors. The study found that patients with IMRDs treated with JAK inhibitors showed reduced immune responses compared to healthy controls, indicating a potential decrease in protection against herpes zoster infection and reactivation. This research provides valuable insights into the impact of the vaccine on adaptive humoral and cellular immune responses in this specific patient population. [Extracted from the article]

Researchers from Cleveland Clinic Children's Hospital conducted a study on pediatric solid organ transplant candidates to assess incomplete immunity to varicella and measles. The study found that a significant percentage of candidates had incomplete immunity to these viruses, despite efforts to optimize immunity through additional vaccine doses. The research highlights the importance of timely vaccination for this vulnerable population, especially during periods of increased viral activity. Future research should focus on addressing strategies and understanding barriers to ensure adequate vaccination prior to transplantation. [Extracted from the article]

A recent study conducted by researchers at the Beijing Center for Disease Prevention and Control in China evaluated the effectiveness of emergency varicella vaccination during an outbreak at an elementary school in Beijing in 2019. The study found that emergency vaccination with the first and second doses of the varicella vaccine significantly reduced the incidence rates of varicella, offering incremental vaccine effectiveness. The research highlights the importance of early initiation of emergency varicella vaccination to mitigate disease outbreaks in settings with incomplete vaccine coverage. For more information, the full article can be accessed for free at https://doi.org/10.3390/vaccines12101184. [Extracted from the article]

A study conducted by the Medical University of Bialystok in Poland analyzed the clinical manifestations and outcomes of Varicella-Zoster Virus (VZV) reactivation in the central nervous system (CNS) in immunocompetent children. The study found that VZV, which can cause herpes zoster (HZ), can infrequently manifest as a neuroinfection. The research concluded that neither a history of VZV immunization nor the absence of a skin rash can definitively exclude VZV meningitis, and any seemingly healthy child could develop HZ meningitis. The study highlights the importance of recognizing and treating VZV reactivation in the CNS in children. [Extracted from the article]

A recent study published in Vaccine Weekly provides new insights into the structure and immunogenicity of the varicella zoster virus (VZV), which causes chickenpox and shingles. The study focused on the glycoprotein E (gE) of VZV, which is the primary target for anti-VZV antibodies. Using X-ray crystallography and cryo-electron microscopy, the researchers were able to determine the 3D structure of gE and identify its interactions with neutralizing antibodies. These findings contribute to our understanding of VZV and may inform the development of future herpesvirus vaccines. [Extracted from the article]

A recent study conducted by researchers at the University of Florence in Italy aimed to assess the seroprevalence of anti-varicella antibodies among adults in the province of Florence. The study found that 89.5% of the 430 tested samples were positive for anti-varicella antibodies, indicating previous exposure to the varicella virus. No significant differences were found based on sex or nationality. However, the study highlighted the risk of varicella infection during pregnancy and emphasized the need for targeted immunization strategies, particularly for women of childbearing age. The researchers concluded that while varicella vaccination has had a significant impact on public health in Italy, efforts should be made to reduce the number of susceptible individuals in adulthood through increased promotion of vaccination. [Extracted from the article]

A recent study conducted by researchers at Xiamen University in China has explored the development of a nanoparticle-based vaccine for the Varicella zoster virus (VZV), which is responsible for chickenpox and shingles. The current vaccines for VZV are effective but can cause varicella-like rashes and raise concerns about cell virulence. The researchers developed a safer alternative using nanoparticles displaying the glycoprotein E (gE) on ferritin particles. This nanoparticle antigen elicited strong immune responses in mice, including high levels of neutralizing antibodies and a Th1-biased immune response. The findings suggest that this nanoparticle-based vaccine could be a promising immunogen for the development of varicella and herpes zoster vaccines. [Extracted from the article]

A recent study conducted at the University of Pittsburgh examined the rates of varicella-zoster virus (VZV) pretransplant immunization, exposures, and posttransplant disease among pediatric solid organ transplant (SOT) recipients. The study found that a significant number of children did not receive the recommended two doses of the varicella vaccine before transplantation, and missed vaccination opportunities were more common among children aged 1-4 years. Additionally, VZV exposures and diseases still occurred among these patients. The researchers concluded that optimizing immunization and ensuring patients have a defined VZV serostatus before transplantation are important goals. [Extracted from the article]

A recent study conducted by researchers at Korea University evaluated the cost-benefit of varicella vaccination programs in South Korea. The study utilized data from South Korea's health databases to estimate the burden of varicella and vaccination records. The findings showed that both one-dose and two-dose vaccination programs were cost-effective compared to no vaccination, with substantial societal cost savings. Implementing either a one-dose or two-dose varicella vaccination regimen in South Korea could lead to cost reductions and improved public health outcomes. However, other factors such as disease severity and transmission dynamics should also be considered. [Extracted from the article]

A recent study conducted by researchers at the National Skin Center in Singapore provides valuable information on the herpes zoster virus, which is responsible for causing conditions such as herpes zoster and post-herpetic neuralgia. The study discusses the epidemiology, pathogenesis, clinical features, diagnosis, management, and vaccination strategies for these conditions. It emphasizes the importance of early initiation of antivirals and the use of anticonvulsants or tricyclic antidepressants for high-risk patients. The study also highlights the effectiveness of the recombinant zoster vaccine in preventing herpes zoster. With the majority of adults in Singapore at risk of developing herpes zoster, it is crucial for clinicians to be knowledgeable about its diagnosis and management. [Extracted from the article]

A recent report from the University of Freiburg in Germany discusses the variable clinical courses of bone marrow failure (BMF) in children following varicella zoster virus (VZV) infection or VZV vaccination. The study highlights the life-threatening nature of VZV-associated BMF, with some patients requiring hematopoietic stem cell transplantation (HSCT) for treatment. The research emphasizes the importance of early detection and appropriate management of this condition. The study has been peer-reviewed and provides valuable insights into the understanding of VZV-related BMF. [Extracted from the article]

A clinical trial, NCT06482216, is currently underway to investigate the relationship between varicella-zoster virus (VZV) antibody levels and the risk of subsequent varicella breakout. The trial consists of two parts: a retrospective cohort study and a prospective cohort study. Sinovac (Dalian) Vaccine Technology Co., Ltd. is conducting the trial, which is currently in the recruitment phase. The article explores the importance of varicella vaccines in pediatrics, the role of antibodies in immunization, and the use of immunoglobulins in clinical research and the development of biological products. It emphasizes the significance of clinical trials and studies in public health and the control of communicable diseases. [Extracted from the article]

An open-label clinical trial, NCT06484686, is being conducted to evaluate the immunity persistence of the live attenuated varicella vaccine at 6 and 10 years after booster dose immunization. The trial is being conducted by Sinovac (Dalian) Vaccine Technology Co., Ltd. The study aims to assess the seropositive rate and geometric mean titer of varicella-zoster virus antibodies at 6 and 10 years after booster vaccination. The trial is currently in the recruitment phase and is expected to be completed by September 2026. [Extracted from the article]

A recent research article published in Biomolecules explores the link between the varicella-zoster virus (VZV), autoimmune diseases, and the role of the recombinant zoster vaccine (RZV). The VZV is responsible for causing varicella (chickenpox) and herpes zoster (shingles). Patients with autoimmune diseases have a higher risk of developing shingles due to compromised immune responses. The introduction of new immunosuppressive agents has expanded treatment options for autoimmune diseases but has also increased the risk of shingles. The adjuvanted RZV is considered safe and effective, even in immunocompromised patients, and its widespread adoption may reduce the health and socioeconomic burdens of shingles. The article provides an overview of the link between VZV and autoimmune diseases, assesses the risk of shingles associated with immunosuppressant use, and discusses the benefits and risks of using RZV in patients with autoimmune diseases. [Extracted from the article]

A recent report from the University of Health Sciences discusses a case of a child with natural killer cell deficiency who experienced a dual infection of the varicella zoster virus (VZV) strain and herpes simplex virus-1 (HSV-1) after receiving the varicella vaccine. The child presented with a rash, encephalopathy, and respiratory distress. The study emphasizes the importance of promptly and aggressively treating vesicular rashes in immunocompromised patients who have been inadvertently vaccinated. The research suggests that antiviral therapy should be initiated in these cases. [Extracted from the article]

A study conducted by the University of Foggia in Italy examined the effectiveness of the combined measles-mumps-rubella-varicella (MMRV) vaccine, Priorix-TetraTM, against varicella (chickenpox) in real-world conditions. The study found that a single dose of the MMRV vaccine provided 77% effectiveness against varicella of all grades of severity, while two doses provided 93% effectiveness. Additionally, the study found that a single dose of the monovalent varicella vaccine provided 72% effectiveness against varicella. The researchers concluded that Priorix-TetraTM is an effective vaccine and recommended the two-dose schedule for optimal immunization programs. [Extracted from the article]

A recent study conducted in Shanghai, China compared the effectiveness of a two-dose varicella vaccine regimen to a one-dose regimen in preventing varicella infection in children. The study included 3,838 children and found that the two-dose regimen had a higher effectiveness of 81.7% compared to 60.3% for the one-dose regimen. The researchers concluded that the two-dose regimen was more effective in preventing varicella infection. This study provides evidence supporting the use of a two-dose varicella vaccine regimen in children. [Extracted from the article]

A study conducted in Vietnam evaluated the safety and immunogenicity of the SKYVaricella vaccine in healthy Vietnamese children aged 12 months to 12 years. The study involved 201 children divided into two age groups. The results showed that the vaccine had a robust immunogenic response and a favorable safety profile, with no Grade 3 adverse events observed. The findings suggest that the SKYVaricella vaccine could be included in pediatric vaccination programs as a reliable preventive option against varicella. [Extracted from the article]

A research study conducted by Dnipro State Medical University in Ukraine explores the challenges of managing lice infestation and varicella (chickenpox) in children, particularly in crisis situations such as war and mass migration. The study presents a case of a 10-year-old girl with co-infection of head lice and varicella, complicated by folliculitis. The researchers highlight the need for updated clinical protocols and healthcare provider education in crisis contexts, as well as the effectiveness of oral ivermectin in treating lice infestation when topical treatments are not feasible. They also recommend integrating varicella vaccination into national immunization schedules to control epidemic processes. [Extracted from the article]

A recent study conducted by the University of Missouri School of Medicine provides new findings on varicella, a highly contagious disease caused by the varicella-zoster virus. The study highlights the wide range of clinical presentations of varicella and its potential to cause severe life-threatening disease in infants, particularly those born to nonimmunized individuals. The research also discusses the natural history of varicella-zoster infection in pregnant individuals, infants with congenital varicella syndrome, and infants with postnatal varicella infection. Additionally, the study offers guidance on isolation recommendations, chemoprophylaxis for exposed hospitalized infants, risk factors for developing disseminated disease, and the approach to treatment of infected infants. [Extracted from the article]

A recent report from the University of Iowa discusses the findings of a study on pediatric vaccines. The study focuses on serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation following varicella vaccination. The researchers found 15 cases of varicella vaccine meningitis in immunocompetent children and adolescents, with the median age being 11 years. They also discovered five additional cases of serious neurological events. Although the number of adverse events is low, the researchers recommend documenting those caused by the vaccine virus. [Extracted from the article]

A recent study conducted in South Korea examined the effectiveness of a 2-dose varicella (chickenpox) vaccination in preventing the disease. The study used national surveillance data and the national immunization registry to analyze the vaccine's effectiveness. The results showed that the 2-dose vaccination strategy had a VE of 98.6%, while the 1-dose strategy had a VE of 16.8%. These findings suggest that the 2-dose vaccination strategy can be an effective way to prevent varicella. The research was supported by the Korea Disease Control and Prevention Agency and conducted by researchers from Korea University. [Extracted from the article]

A study conducted by Rutgers University New Jersey Medical School provides new insights into Herpes Zoster Virus (HZ) infection in pregnancy. The research highlights that HZ infection occurs in approximately 4 people per 1000 in the general US population each year, regardless of prior varicella infection or vaccination status. The study explores the implications of HZ infection during pregnancy, including potential immunologic sequelae, and strategies for prevention and treatment. While maternal HZ infection during pregnancy is not uncommon, there is limited evidence of intrauterine transmission to the fetus. The research aims to contribute to the existing literature on this topic. [Extracted from the article]

A recent study from Johns Hopkins University discusses the impact of delayed vaccination schedules on the incidence rates of measles, mumps, rubella (MMR), and varicella due to the COVID-19 pandemic. The research highlights the importance of herd immunity and the risks it poses to both immunocompetent children and immunocompromised individuals in the community. The study also explores the safety and efficacy of live-attenuated vaccines (MMR and varicella) in pediatric patients before and after solid organ transplants. The findings aim to provide guidance on the use of these vaccines in the care of pediatric patients undergoing organ transplants. [Extracted from the article]

A recent study conducted by researchers at Konkuk University in Seoul, South Korea, has explored the potential of a new vaccine for the herpes zoster virus (HZV), which causes varicella and shingles. The researchers compared the efficacy of recombinant baculoviral vector vaccines (AcHERV) with a live attenuated vaccine strain, vOka. The results showed that the AcHERV-gE-gB vaccine candidate demonstrated similar or higher levels of antibodies and cell-mediated immune responses compared to vOka, suggesting that it could be a promising alternative for preventing varicella and providing therapeutic benefits against HZV. This research was supported by the Ministry of Food And Drug Safety and the Korean Health Technology R&D Project. [Extracted from the article]

A recent study conducted by researchers at the University of Campania in Naples, Italy, examined the seroprevalence of measles, varicella, mumps, and rubella among trainee obstetricians in Southern Italy. The study found that a percentage of the trainee obstetricians tested did not have effective immunological coverage against at least one of these vaccine-preventable diseases, particularly mumps. The researchers suggest extending surveillance to other professionals in contact with vulnerable patients and increasing awareness of vaccination campaigns. This information is valuable for evaluating preventive strategies to avoid infectious outbreaks. [Extracted from the article]

A recent study conducted by the University of Leicester examined the seroprotection rates for measles, varicella zoster, and rubella among adult migrants living in Leicester, UK. The study found that seroprotection rates were high for varicella zoster (98%) and rubella (92.6%), but lower for measles (89.3%). Younger migrants and those from Europe and Central Asia were more likely to lack seroprotection against measles. Additionally, a significant proportion of migrants were unsure about their vaccination and disease history, and self-reported vaccine/disease history was not a reliable predictor of seroprotection. These findings highlight the need for further research on barriers to vaccine uptake in migrant populations and individualized risk profiles based on demographic and migration factors. [Extracted from the article]

A recent study conducted by investigators at Rutgers University - The State University of New Jersey highlights the potential for transmission of chickenpox (varicella) in healthcare settings. The study presents a case report of a patient who acquired chickenpox during a prolonged hospital stay through a healthcare worker (HCW) who had contracted chickenpox after exposure to the patient's roommate with herpes zoster. The case emphasizes the importance of verifying the immunization status of HCWs, mandating immunity, furloughing unimmunized staff after exposure to herpes zoster, and implementing postexposure prophylaxis to minimize the risk of transmission. The study aims to provide educational value and relevant learning points for healthcare professionals. [Extracted from the article]

A recent study conducted by the University of Chile has found that the use of specific immunoglobulin for varicella zoster virus as prophylaxis in newborns reduces the risk of neonatal chickenpox but does not eliminate it. The researchers presented a case of a newborn who developed severe chickenpox despite receiving prophylaxis with immunoglobulin. The study highlights the importance of further research and management recommendations for neonatal chickenpox, especially in countries where the varicella vaccine has recently been incorporated into the national immunization program. [Extracted from the article]

A study conducted at Cairo University in Egypt has developed a new potentiometric biosensor to determine the potency and stability of the varicella vaccine. The biosensor, which uses an anti-varicella monoclonal antibody and tetrabutyl ammonium bromide, was found to be superior to traditional cell culture methods in terms of analysis time and cost. The biosensor was also able to differentiate between intact and degraded viral content, demonstrating its reliability for evaluating the efficacy and stability of the vaccine. This research has been peer-reviewed and published in Analytical Biochemistry. [Extracted from the article]

A recent report from Houston Methodist Hospital discusses the development of shingles in a patient who had completed the recombinant varicella-zoster virus (VZV) vaccine series while taking tofacitinib, a medication used to treat autoimmune diseases. Shingles, caused by the reactivation of the VZV, is more common in older individuals and those with weakened immune systems. The researchers found that despite prior vaccination, the patient still developed shingles. The recombinant VZV vaccine is generally effective at reducing the risk of shingles, but this case highlights the need for further investigation in patients taking tofacitinib. [Extracted from the article]

A recent study conducted by GlaxoSmithKline plc has found that there is a slightly increased risk of febrile convulsions (FC) after the first dose of the quadrivalent measles, mumps, rubella, and varicella (MMRV) vaccine compared to the MMR and varicella (MMR+V) vaccines administered separately. However, the overall risk of FC is low compared to other causes such as natural exposure to pathogens or routine vaccination. The study suggests that the benefits of the MMRV vaccine, including fewer injections and higher coverage, outweigh the potential risks. It is recommended to monitor vaccinees for fever during the first two weeks after vaccination. [Extracted from the article]

A study conducted by researchers at the University of Padova in Italy explores the use of varicella vaccines in hemodialysis patients. Varicella Zoster Virus (VZV) infection can lead to severe complications in adults and immunocompromised individuals. The study suggests that vaccination against VZV can prevent primary infection and reactivation in hemodialysis patients, who are at a higher risk due to immunodepression. Two vaccines, the live attenuated Zoster Vaccine (LZV) and the Recombinant Zoster Vaccine (RZV), are currently available, with RZV showing greater efficacy. The researchers recommend promoting VZV vaccination in hemodialysis patients, particularly those with future transplant opportunities. [Extracted from the article]

A study conducted by researchers at the Wuxi Center for Disease Control and Prevention in China aimed to assess the effectiveness of the varicella vaccine in preventing varicella outbreaks. The study analyzed varicella surveillance data and vaccination data from children aged 1-6 years in Wuxi between January 2016 and December 2020. The results showed that districts with higher varicella vaccination rates had a lower proportion of varicella cases. The researchers concluded that two-dose varicella vaccination is recommended as an effective health intervention to prevent varicella in Wuxi and should be included in routine childhood immunization programs. [Extracted from the article]

A recent report from Beijing Jiaotong University discusses new research on the herpes zoster virus, which causes the disease known as shingles. The study focuses on the development of a potential vaccine for shingles using recombinant adenoviruses expressing a specific protein from the varicella-zoster virus (VZV). The researchers found that the vaccine candidate induced similar immune responses in mice as the currently available shingles vaccines. This study suggests that the recombinant adenoviruses expressing VZV protein could be a promising candidate for further development as a shingles vaccine. [Extracted from the article]

A study conducted by researchers at Sylhet Agricultural University in Bangladesh explores the development of a polyvalent multiepitope subunit vaccine for the Varicella Zoster Virus (VZV), which causes chickenpox and shingles. The researchers used bioinformatics approaches to select six glycoproteins crucial for viral infection and identified cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B cell linear (LBL) epitopes. They designed two vaccine constructs that demonstrated high antigenicity, solubility, stability, and compatibility with Toll-like receptors (TLRs). The study lays the foundation for a comprehensive solution to VZV infections and offers insights into tailored vaccine design strategies against complex viral pathogens. Further validation through in vivo studies is needed to confirm the effectiveness of the vaccine. [Extracted from the article]

A study conducted by Showa Women's University in Tokyo, Japan, aimed to understand the vaccine and infection histories of nursery teachers for measles, mumps, rubella, and varicella. The researchers sent questionnaires to 5,000 nursery teachers and received 1,620 responses. The study found that the proportions of susceptibility for measles, rubella, and varicella were higher, ranging from 22-23%, while the proportion for mumps was 42%. The research concluded that susceptibility to measles and rubella was higher among respondents in their 30s, while susceptibility to varicella and mumps was higher among respondents in their 20s. [Extracted from the article]

A study conducted by researchers at Qatar University evaluated the real-world effectiveness of the varicella vaccine among children and adolescents in Qatar from 2017 to 2019. The study included 862 cases of varicella and 5454 matched controls. The results showed that a single dose of the vaccine reduced the odds of varicella infection by 56%, while a two-dose vaccination reduced the odds by 86%. The researchers concluded that a two-dose varicella vaccination provides reasonable protection against varicella infection in this multicultural setting. [Extracted from the article]

A recent study conducted at the University of Catania in Italy examined the vaccination choices made by pregnant women. The study found that while the majority of women were vaccinated against Measles, Mumps, Rubella (MMR) and Diphtheria, Tetanus, and Pertussis (DTaP), vaccination rates for Varicella, Human Papillomavirus (HPV), and Seasonal Influenza were lower. Lack of information was cited as the main reason for refusal of these vaccines. The study also found that younger women were more aware of HPV vaccination, suggesting improvements in the national vaccination program. The researchers concluded that increasing knowledge about vaccination and addressing social determinants are necessary to improve vaccination rates among women of childbearing age. [Extracted from the article]

Keywords: Antibodies; Biological Products; Blood Proteins; German Measles; Health and Medicine; Immunization; Immunoglobulins; Immunology; Infectious Disease; Infectious Diseases and Conditions; Measles; Mouth Diseases and Conditions; Mumps; Paramyxoviridae Infections; Parotid Diseases and Conditions; Parotitis; Pediatrics; Proteins; Public Health; RNA Viruses; Rubella; Rubulavirus Infections; Salivary Gland Diseases and Conditions; Stomatognathic Diseases and Conditions; Vaccination; Vaccines; Varicella; Viral Vaccines; Virology EN Antibodies Biological Products Blood Proteins German Measles Health and Medicine Immunization Immunoglobulins Immunology Infectious Disease Infectious Diseases and Conditions Measles Mouth Diseases and Conditions Mumps Paramyxoviridae Infections Parotid Diseases and Conditions Parotitis Pediatrics Proteins Public Health RNA Viruses Rubella Rubulavirus Infections Salivary Gland Diseases and Conditions Stomatognathic Diseases and Conditions Vaccination Vaccines Varicella Viral Vaccines Virology 305 305 1 10/30/23 20231103 NES 231103 2023 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- New study results on viral vaccines have been published. The majority of children developed protective antibodies following vaccination (107 of 149 [72%] varicella, 130 of 152 [86%] measles, 100 of 120 [83%] mumps, and 124 of 125 [99%] rubella). [Extracted from the article]

Finland was the first Nordic country to start a chickenpox vaccination programme, and the vaccinations for all children under the age of 12 who had not had chickenpox were exceptionally extensive. Keywords: Biological Products; Chickenpox; Chickenpox Vaccines; Communicable Disease Control; DNA Virus Infections; DNA Viruses; Environment and Public Health; Finnish Institute for Health and Welfare; Health and Medicine; Herpes Virus Vaccines; Herpesviridae Infections; Immunization; Immunization and Public Health; Infectious Diseases and Conditions; Pediatrics; Public Health; Public Health Practice; Vaccination; Vaccines; Varicella; Varicella-Zoster Virus; Viral Vaccines; Virology EN Biological Products Chickenpox Chickenpox Vaccines Communicable Disease Control DNA Virus Infections DNA Viruses Environment and Public Health Finnish Institute for Health and Welfare Health and Medicine Herpes Virus Vaccines Herpesviridae Infections Immunization Immunization and Public Health Infectious Diseases and Conditions Pediatrics Public Health Public Health Practice Vaccination Vaccines Varicella Varicella-Zoster Virus Viral Vaccines Virology 8130 8130 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A recent study by the Finnish Institute for Health and Welfare (THL) reveals that a two-dose varicella vaccination programme to all children under the age of 12 who had not had chickenpox reduced the number of health centre appointments related to the disease significantly and fast in all age groups. [Extracted from the article]

Keywords: Le Kremlin-Bicetre; France; Europe; Betaherpesvirinae; Biological Products; Chickenpox; Corneal Diseases and Conditions; Cytomegalovirus; DNA Virus Infections; DNA Viruses; Drugs and Therapies; Eye Diseases and Conditions; Health and Medicine; Herpes Simplex Virus; Herpes Zoster; Herpes Zoster Virus; Herpesviridae; Herpesviridae Infections; Herpesvirus; Herpesvirus Diseases and Conditions; Immunization; Infectious Diseases and Conditions; Keratitis; Ophthalmology; Vaccines; Varicella; Varicella-Zoster Virus; Viral; Viral Skin Diseases and Conditions; Virology EN Le Kremlin-Bicetre France Europe Betaherpesvirinae Biological Products Chickenpox Corneal Diseases and Conditions Cytomegalovirus DNA Virus Infections DNA Viruses Drugs and Therapies Eye Diseases and Conditions Health and Medicine Herpes Simplex Virus Herpes Zoster Herpes Zoster Virus Herpesviridae Herpesviridae Infections Herpesvirus Herpesvirus Diseases and Conditions Immunization Infectious Diseases and Conditions Keratitis Ophthalmology Vaccines Varicella Varicella-Zoster Virus Viral Viral Skin Diseases and Conditions Virology 1998 1998 1 10/16/23 20231016 NES 231016 2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Herpesvirus Diseases and Conditions - Herpes Zoster Virus have been published. [Extracted from the article]